Antibody protein sequencing: turning a dwindling reagent into a permanent one

The two routes and what each needs

1. From the cell, which is far easier, while you still have it. If the hybridoma or the producing cell line is alive, the variable region sequences are recovered from its messenger RNA by amplification and sequencing. It is cheap, fast and unambiguous. Do it while the line is healthy rather than after it is not.
2. From purified protein, when the cell is gone. De novo sequencing by mass spectrometry reconstructs the sequence from overlapping peptides. It needs a few hundred micrograms of purified antibody, several proteases to produce overlapping coverage, and it is a considerably larger analytical exercise.
3. Insist on full coverage of the complementarity determining regions. The binding regions are where errors matter and where coverage is hardest, because they are the most variable. A report with gaps in those loops has not delivered a usable sequence, whatever the overall coverage percentage says.
4. Watch the isobaric residues. Leucine and isoleucine have identical mass and cannot be distinguished by ordinary mass spectrometry, and there are similar traps. A good provider states how it resolved them, or states that it did not, and an unresolved position has to be tested by expression.
5. Prove the sequence by expressing it. The only real validation is to express the recombinant antibody from the reported sequence and show it binds like the original, in the assay you care about. A sequence that has not been expressed is a hypothesis, and the expression test should be part of the project.

What to agree before sending material

Who owns the resulting sequence, whether the provider may retain or reuse it, what the deliverable format is, and whether expression validation is included or extra. Ownership of a sequence derived from your reagent is a term worth reading closely.

Agree the acceptance criteria: coverage across the variable regions, how ambiguous positions are reported, and what happens if coverage falls short. A report with gaps and no remedy clause is a poor outcome nobody planned for.

Preparing the sample for an antibody sequencing service

Send purified, carrier-free antibody in a simple buffer. Bovine serum albumin, gelatin and other stabilisers in a formulated reagent all interfere, and ascites or serum-derived material brings the host's own immunoglobulin with it.

Send more than the minimum. A repeat digest with another protease is often what closes a coverage gap, and it is much faster if the material is already there.

After the sequence arrives: antibody expression and comparison

Express it, purify it, and compare against the original in the assay you actually use, not only in a binding measurement. Then bank the plasmid and the sequence somewhere that is not one laptop.

Record the sequence with the reagent's history: which clone, which lot it was derived from and who sequenced it. That record is what makes the reagent citable in a methods section a decade later.

protein sequencing by mass spectrometry, and the two strategies

Mass spectrometry reads sequence in two ways. Bottom-up digests the protein, usually with trypsin, sequences the peptides by fragmentation and reassembles the coverage, which is sensitive, routine and leaves gaps wherever a peptide is missed. Top-down fragments the intact protein, which preserves the connection between modifications on one molecule and is far more demanding on the instrument. De novo sequencing, reading a sequence with no database, needs complementary enzymes and high mass accuracy, and it is how an antibody with no known sequence is read. Ask which the quote covers, and what coverage it guarantees.

n terminal sequencing, and what it answers

Amino terminal sequencing reads the first residues of a protein directly, by Edman degradation or by a mass spectrometry equivalent, and it answers questions a database search cannot: where a mature protein actually starts after signal peptide cleavage, whether a product is clipped, and which of several possible processing forms is in the tube. It needs a clean, single species on a membrane or in solution, which usually means a gel band. Where the sequence is known, a peptide map is cheaper; where the start site is the question, this is the method.

A plexin d1 antibody and sequencing an existing clone

A plexin d1 antibody reports a guidance receptor with few validated clones, and where a working hybridoma exists but its sequence does not, sequencing the antibody is what makes it a recombinant reagent that can be remade forever. That conversion also fixes the lot to lot variation a polyclonal against this target has.

amino acid sequencing and when it is still needed

amino acid sequencing reads a protein directly rather than inferring it from DNA, which is what a purified protein of unknown origin, a blocked terminus or a confirmed processing site still needs. Mass spectrometry answers most of these faster, so the classical chemistry is reserved for the terminal residues it reads best.

Common questions

Can an antibody be sequenced from purified protein alone?

Yes, by de novo mass spectrometry using several proteases to generate overlapping peptides. It needs a few hundred micrograms of pure antibody and it is harder and more expensive than sequencing from the cell that makes it.

How much antibody do protein sequencing services need?

Typically a few hundred micrograms of purified, homogeneous material. Contaminating immunoglobulin from serum or a carrier protein in the formulation complicates the analysis considerably, so supply carrier-free purified material.

How accurate is de novo antibody sequencing?

Good providers achieve high coverage, and the difficult part is the binding loops and residues with identical mass. Expressing the sequence and showing the recombinant binds like the original is the only proof that settles it.

Why sequence a hybridoma antibody at all?

To make it permanent. A sequence can be expressed indefinitely, reformatted into any isotype or fragment, produced anywhere and shared, while a hybridoma drifts, can be lost and exists in one freezer.

Is hybridoma sequencing easier than sequencing the protein?

Far easier, while the line is alive. If the hybridoma or the producing cell line is healthy, the variable region sequences are recovered from its messenger RNA by amplification and sequencing, which is cheap, fast and unambiguous. Sequencing from purified protein is the route for when the cell is gone, so do it while the line is still growing.

Browse by service class

• Compare Gene synthesis on advertised prices